To include your compound in the COVID-19 Resource Center, submit it here.

China's SARI acquiring Nerviano

China investment company SARI will acquire a 90% stake in cancer company Nerviano Medical Sciences s.r.l. (Nerviano, Italy) for about €300 million ($356.3 million), which includes an equity

Read the full 289 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE